Is Soleno Therapeutics Stock a Good Investment?
Soleno Therapeutics Investment Advice | SLNO |
- Examine Soleno Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Soleno Therapeutics' leadership team and their track record. Good management can help Soleno Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Medical Equipment space and any emerging trends that could impact Soleno Therapeutics' business and its evolving consumer preferences.
- Compare Soleno Therapeutics' performance and market position to its competitors. Analyze how Soleno Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Soleno Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Soleno Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Soleno Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Soleno Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Soleno Therapeutics Stock
Researching Soleno Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.79. Soleno Therapeutics last dividend was issued on the 6th of October 2017. The entity had 1:15 split on the 26th of August 2022.
To determine if Soleno Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Soleno Therapeutics' research are outlined below:
| Soleno Therapeutics generated a negative expected return over the last 90 days | |
| Soleno Therapeutics has high historical volatility and very poor performance | |
| Soleno Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
| Over 97.0% of the company shares are owned by institutional investors |
Soleno Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Soleno Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Soleno Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Soleno Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.15 B.Basic technical analysis of Soleno Stock
As of the 31st of January, Soleno Therapeutics has the Coefficient Of Variation of (2,239), variance of 10.77, and Risk Adjusted Performance of (0.03). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Soleno Therapeutics, as well as the relationship between them.Soleno Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Soleno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Soleno Therapeutics' Outstanding Corporate Bonds
Soleno Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Soleno Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Soleno bonds can be classified according to their maturity, which is the date when Soleno Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Understand Soleno Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Soleno Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.22 | |||
| Coefficient Of Variation | (2,239) | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 19.49 | |||
| Value At Risk | (4.99) | |||
| Potential Upside | 5.14 | |||
| Skewness | 1.45 | |||
| Kurtosis | 5.13 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 2.22 | |||
| Coefficient Of Variation | (2,239) | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.77 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 19.49 | |||
| Value At Risk | (4.99) | |||
| Potential Upside | 5.14 | |||
| Skewness | 1.45 | |||
| Kurtosis | 5.13 |
Consider Soleno Therapeutics' intraday indicators
Soleno Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Soleno Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Soleno Therapeutics time-series forecasting models is one of many Soleno Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Soleno Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Soleno Stock media impact
Far too much social signal, news, headlines, and media speculation about Soleno Therapeutics that are available to investors today. That information is available publicly through Soleno media outlets and privately through word of mouth or via Soleno internal channels. However, regardless of the origin, that massive amount of Soleno data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Soleno Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Soleno Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Soleno Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Soleno Therapeutics alpha.
Soleno Therapeutics Corporate Management
| Kristen MS | Senior Operations | Profile | |
| Dr MBA | Senior Development | Profile | |
| Patricia MPH | Senior Affairs | Profile | |
| PharmD MBA | Senior Affairs | Profile | |
| Meredith MBA | Chief Officer | Profile | |
| Anish MD | CEO and President | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Soleno Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.